Abstract
Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Current Pharmacogenomics and Personalized Medicine
Title:Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors
Volume: 16 Issue: 2
Author(s): Wei-Hua Shao, Lei-Yun Wang and Ji-Ye Yin*
Affiliation:
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008,China
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Abstract: Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Export Options
About this article
Cite this article as:
Shao Wei-Hua , Wang Lei-Yun and Yin Ji-Ye *, Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors, Current Pharmacogenomics and Personalized Medicine 2018; 16 (2) . https://dx.doi.org/10.2174/1875692116666180821152601
DOI https://dx.doi.org/10.2174/1875692116666180821152601 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Bringing Light into the Diagnosis of Skin Disorders - Short Review on Laser Induced Fluorescence Spectroscopy and Optical Coherence Tomography in Dermatology
Current Medical Imaging The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery Computational & Statistical Methodologies to Identify Biomarkers in Cancer
Current Cancer Therapy Reviews Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry The Relevance of Supplemental Vitamin D in Malignancies
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews Selective Gene Amplification for High-Throughput Sequencing
Recent Patents on DNA & Gene Sequences Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry